Google
ABBV — ABBVIE INC (Healthcare >> Drug Manufacturers - General)
ABBV FAQ
What is ABBV's P/E ratio?
ABBVIE INC (ABBV) currently trades at a P/E ratio of 105.42.
What is ABBV's ROE?
ABBVIE INC reports a Return on Equity (ROE) of -55.04%.
What is ABBV's dividend yield?
ABBVIE INC offers a dividend yield of 3.13%.
What is ABBV's Deepscope Quality Score?
Deepscope rates ABBV's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ABBV?
Deepscope's AI Timing Score for ABBV is 96 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ABBV belong to?
ABBVIE INC is classified under the Healthcare >> Drug Manufacturers - General sector on the NYSE exchange.
|
USD 224.94
Price
7.81
(3.60%)
Day Change
|
|
|---|
ABBV, the overall quality is not good ( Quality = 46) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
2785
|
| Magic Formula Rank by ROE |
2785
|
| Magic Formula Rank by ROIC |
2740
|
| Price | 224.94 |
| PBV / Sector |
-58.02 / 2.83
|
| Earning Per Share | 2.13 |
| PE / Sector |
105.42 / 23.79
|
| PEG or PE/Growth / Sector |
-4.39 / 0.07
|
| Average 1M Daily Value |
914.09 M
|
| Average 1W Daily Value |
1,064.71 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
66% |
| Return to Investors |
|
33% |
| Registration Details |
| Analyze Date | 2026-06-05 09:12:02 |
| Symbol | ABBV |
| Name | ABBVIE INC |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 1,766.79 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 383,623.73 / 233,824.82 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
Phone: 847 932 7900
Website: https://www.abbvie.com
Employees: 57,000
Description: AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
